Previous 10 | Next 10 |
2023-03-10 12:40:14 ET Gainers: Euda ( EUDA ) +94% . Altamira Therapeutics ( CYTO ) +40% . Unicycive ( UNCY ) +37% . Cazoo Group ( CZOO ) +27% . Tenon Medical ( TNON ) +20% . PLAYSTUDIOS ( MYPS ) +19% . Solo Brand...
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA™, a lead...
Evoke Pharma ( NASDAQ: EVOK ) stock rose ~4% on Monday after the company said that a joint stipulation of dismissal was filed in the Gimoti's patent infringement case in the U.S. District Court for the District of New Jersey. The filing of the stipulation arises fro...
SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that a joint stipula...
SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitle...
Evoke Pharma ( NASDAQ: EVOK ) is trading 7.1% higher after it received U.S. patent for Treatment of moderate and severe gastroparesis for Gimoti. This patent expires in 2038 and covers the methods for treating moderate-to-severe gastroparesis with metoclopramide via an in...
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the United Stat...
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Tr...
Evoke Pharma, Inc. (EVOK) Q3 2022 Results Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - President and Chief Executive Officer Chris Quesenberry - Chief Commerci...
Evoke Pharma press release ( NASDAQ: EVOK ): Q3 GAAP EPS of -$0.60 beats by $0.06 . Revenue of $0.83M (-10.8% Y/Y) beats by $0.26M . 80% increase in GIMOTI ® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compare...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 141.4% to $0.3138 on volume of 161,736,322 shares ENDRA Life Sciences Inc. (NDRA) rose 13.7% to $0.117778 on volume of 79,058,950 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 27.2% to $0.1042 on volum...
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK)...